Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MicroTech to Raise up to $254 Million in Hong Kong IPO for Diabetes Products

publication date: Oct 8, 2021

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the pricing range. MicroTech is the only China company with an approved patch insulin pump, which was launched in 2018. The company also offers a traditional blood glucose monitoring device and is developing a continuous blood glucose monitoring device. It has an additional six diabetes products in early development. MicroTech would have a market capitalization of $1.3 billion at the top of the range. More details....

Stock Symbol: (HK: 2235)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital